Label: information for the user
Exforge HCT 5mg/160mg/12,5mg film-coated tablets
Exforge HCT 10mg/160mg/12,5mg film-coated tablets
Exforge HCT 5mg/160mg/25mg film-coated tablets
Exforge HCT 10mg/160mg/25mg film-coated tablets
Exforge HCT 10mg/320mg/25mg film-coated tablets
amlodipino/valsartán/hidroclorotiazida
Read this label carefully before starting to take this medication, as it contains important information for you.
1.What is Exforge HCT and for what it is used
2.What you need to know before starting to take Exforge HCT
3.How to take Exforge HCT
4.Possible adverse effects
5.Storage of Exforge HCT
6.Contents of the package and additional information
Exforge HCT tablets contain three substances called amlodipine, valsartan and hydrochlorothiazide. All these substances help control high blood pressure.
As a result of the three mechanisms, blood vessels relax and blood pressure decreases.
Exforge HCT is used to treat high blood pressure in adult patients whose blood pressure is already controlled while taking amlodipine, valsartan and hydrochlorothiazide and who may benefit from taking a tablet that contains the three substances.
Do not take Exforge HCT
Do not take Exforge HCT and inform your doctor if you are affected by any of the above cases.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Exforge HCT
Your doctor may monitor your renal function, blood pressure, and electrolyte levels (e.g. potassium) at regular intervals.
See also the information under the heading "Do not take Exforge HCT".
Inform your doctor if you are affected by any of the cases mentioned.
Children and adolescents
Exforge HCT is not recommended for use in children or adolescents under 18 years old.
Older adults (65 years and older)
Exforge HCT can be used in people aged 6 years and older at the same dose as used in other adults and in the same way as they have already taken the three substances called amlodipine, valsartan, and hydrochlorothiazide. Renal pressure should be monitored regularly in elderly patients, particularly those taking the maximum dose of Exforge HCT (10 mg/320 mg/25 mg).
Other medications and Exforge HCT
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication. Your doctor may need to adjust your dose and/or take other precautions. In some cases, you may need to stop taking one of the medications. This is especially important if you are taking any of the medications listed below:
Do not take with:
Use with caution with:
Exforge HCT with food, drinks, and alcohol
People who have been prescribed Exforge HCT should not consume grapefruit or grapefruit juice. This is because grapefruit and grapefruit juice may cause an increase in the blood levels of the active ingredient amlodipine, which may cause unpredictable reductions in Exforge HCT's blood pressure-lowering effects.Consult your doctor before drinking alcohol. Alcohol may significantly lower your blood pressure and/or increase the risk of dizziness or fainting.
Pregnancy and breastfeeding
Pregnancy
You must inform your doctorif you are pregnant,if you suspect you may beor if you plan to become pregnant. Your doctor will usually advise you to stop taking Exforge HCT before becoming pregnant or as soon as you become pregnant, and recommend taking another antihypertensive medication instead. Exforge HCT is not recommended for use at the beginning of pregnancy and should not be administered after the third month of pregnancy as it may cause serious harm to your baby when administered from that point onwards.
Lactation
Inform your doctorifyou plan to start or are breastfeeding.Amlodipine has been shown to pass into breast milk in small amounts.Exforge HCT is not recommended for use during this period. Your doctor may decide to administer a more suitable treatment if you want to breastfeed, especially for newborns or premature babies.
Consult your doctor or pharmacist before using any medication.
Driving and operating machinery
As with other medications used to treat high blood pressure, Exforge HCT may cause dizziness, drowsiness, nausea, or headaches. If you experience these symptoms, do not drive or operate tools or machinery.
Follow exactly the administration instructions for this medication as indicated by your doctor. If in doubt, consult your doctor again. This will help you achieve the best results and reduce the risk of adverse effects. .
The usual dose of Exforge HCT is one tablet per day.
Depending on your response to treatment, your doctor may suggest a higher or lower dose.
Do not exceed the prescribed dose.
If you take more Exforge HCT than you should
If you have accidentally taken too many Exforge HCT tablets, consult your doctor immediately. You may need medical attention. . Excess fluid may accumulate in the lungs (pulmonary edema) causing difficulty breathing that may develop within 24-48 hours after ingestion.
If you forget to take Exforge HCT
If you forget to take a dose of this medication, take it as soon as you remember and then take the next dose at the usual time. If it is almost time for the next dose, only take the next tablet at the usual time. Do not take a double dose (two tablets at once) to make up for missed doses.
If you interrupt treatment with Exforge HCT
Stopping your treatment with Exforge HCT may cause your condition to worsen. Do not stop taking the medication unless your doctor tells you to.
Always take this medication, even if you feel well
People with hypertension often do not notice any symptoms of their condition. Many people feel fine. It is very important that you take this medication exactly as your doctor has instructed to achieve the best results and reduce the risk of adverse effects. Keep your appointments with your doctor even if you feel well.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
As with any combination that contains three active principles, it cannot be ruled out that side effects associated with each individual component may occur. The side effects observed with Exforge HCT or one of its three active principles (amlodipine, valsartan, and hydrochlorothiazide) appear below and may occur with the use of Exforge HCT.
Some side effects may be severe and require immediate medical attention.
Consult your doctor immediately if, after taking this medicine, you experience any of the following severe side effects:
Frequent (may affect up to 1 in 10 patients):
Infrequent (may affect up to 1 in 100 patients):
Rare (may affect up to 1 in 1,000 patients):
Very rare (may affect up to 1 in 10,000 patients):
Other side effects may include:
Very frequent (may affect more than 1 in 10 patients):
Frequent (may affect up to 1 in 10 patients):
Infrequent (may affect up to 1 in 100 patients):
Rare (may affect up to 1 in 1,000 patients):
Very rare (may affect up to 1 in 10,000 patients):
Frequency not known (the frequency cannot be estimated from available data):
Reporting of side effects:
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national notification system included in theAnexo V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and blister (after CAD/EXP). The expiration date is the last day of the month indicated.
Do not store above 86°F (30°C).
Store in the original packaging to protect it from moisture.
Do not use Exforge HCT if you observe that the packaging is damaged or shows signs of manipulation.
Medicines should not be disposed of through drains or in the trash.Ask your pharmacist how to dispose of the packaging and medications that you no longer need.This will help protect the environment.
Composition ofExforge HCT
Exforge HCT 5mg/160mg/12,5mg film-coated tablets
The active ingredients of Exforge HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 5mg of amlodipine (as amlodipine besylate), 160mg of valsartan, and 12,5mg of hydrochlorothiazide.
The other components are microcrystalline cellulose; crospovidone(type A); anhydrous colloidal silica; magnesium stearate; hypromellose(type of substitution 2910 (3 mPa·s)), macrogol 4000, talc, titanium dioxide (E171).
Exforge HCT 10mg/160mg/12,5mg film-coated tablets
The active ingredients of Exforge HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 10mg of amlodipine (as amlodipine besylate), 160mg of valsartan, and 12,5mg of hydrochlorothiazide.
The other components are microcrystalline cellulose; crospovidone(type A); anhydrous colloidal silica; magnesium stearate; hypromellose(type of substitution 2910 (3 mPa·s)), macrogol 4000, talc, titanium dioxide (E171).
Exforge HCT 5mg/160mg/25mg film-coated tablets
The active ingredients of Exforge HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 5mg of amlodipine (as amlodipine besylate), 160mg of valsartan, and 25mg of hydrochlorothiazide.
The other components are microcrystalline cellulose; crospovidone(type A); anhydrous colloidal silica, magnesium stearate, hypromellose(type of substitution 2910 (3 mPa·s)), macrogol 4000, talc, titanium dioxide (E171), yellow iron oxide (E172).
Exforge HCT 10mg/160mg/25mg film-coated tablets
The active ingredients of Exforge HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 10mg of amlodipine (as amlodipine besylate), 160mg of valsartan, and 25mg of hydrochlorothiazide.
The other components are microcrystalline cellulose; crospovidone(type A); anhydrous colloidal silica, magnesium stearate, hypromellose(type of substitution 2910 (3 mPa·s)), macrogol 4000, talc, yellow iron oxide (E172).
Exforge HCT 10mg/320mg/25mg film-coated tablets
The active ingredients of Exforge HCT are amlodipine (as amlodipine besylate), valsartan, and hydrochlorothiazide. Each film-coated tablet contains 10mg of amlodipine (as amlodipine besylate), 320mg of valsartan, and 25mg of hydrochlorothiazide.
The other components are microcrystalline cellulose; crospovidone(type A); anhydrous colloidal silica, magnesium stearate, hypromellose(type of substitution 2910 (3 mPa·s)), macrogol 4000, talc, yellow iron oxide (E172).
Appearance of the product and contents of the pack
Exforge HCT 5mg/160mg/12,5mg film-coated tablets are oval-shaped, white in color, with«NVR»on one side and«VCL»on the other side. Approximate size: 15mm (length) x 5,9mm (width).
Exforge HCT 10mg/160mg/12,5mg film-coated tablets are oval-shaped, pale yellow in color, with«NVR»on one side and«VDL»on the other side. Approximate size: 15mm (length) x 5,9mm (width).
Exforge HCT 5mg/160mg/25mg film-coated tablets are oval-shaped, yellow in color, with«NVR»on one side and«VEL»on the other side. Approximate size: 15mm (length) x 5,9mm (width).
Exforge HCT 10mg/160mg/25mg film-coated tablets are oval-shaped, yellow-brown in color, with«NVR»on one side and«VHL»on the other side. Approximate size: 15mm (length) x 5,9mm (width).
Exforge HCT 10mg/320mg/25mg film-coated tablets are oval-shaped, yellow-brown in color, with«NVR»on one side and«VFL»on the other side. Approximate size: 19mm (length) x 7,5mm (width).
Exforge HCT is available in packs containing 14, 28, 30, 56, 90, 98, or 280film-coated tablets, in multiple packs with 280film-coated tablets (with 4boxes, each containing 70film-coated tablets, or 20boxes, each containing 14film-coated tablets), and in clinical packs with 56, 98, or 280film-coated tablets in perforated dose blisters.
Not all pack sizes may be marketed in your country.
Marketing authorization holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Irlanda
Responsible for manufacturing
Via Provinciale Schito 131
80058 Torre Annunziata (NA)
Italia
Novartis Farmacéutica S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
España
Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
Alemania
Sophie-Germain-Strasse 10
90443 Nürnberg
Alemania
For more information about this medicinal product, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 | Lietuva SIA „Novartis Baltics“ Lietuvos filialas Tel: +370 5 269 16 50 |
Lietuva Novartis Bulgaria EOOD Teπ.: +359 2 489 98 28 | Luxembourg/Luxemburg Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 |
Ceská republika Novartis s.r.o. Tel: +420 225 775 111 | Magyarország Novartis Hungária Kft. Tel.: +36 1 457 65 00 |
Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 00 | Malta Novartis Pharma Services Inc. Tel:+356 2122 2872 |
Deutschland Novartis Pharma GmbH Tel: +49 911 273 0 | Nederland Novartis Pharma B.V. Tel: +31 88 04 52 111 |
Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 810 | Norge Novartis Norge AS Tlf: +47 23 05 20 00 |
Ελλáδα Novartis (Hellas) A.E.B.E. Τηλ: +30 210 281 17 12 | Österreich Novartis Pharma GmbH Tel: +43 1 86 6570 |
España Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00 | Polska Novartis Poland Sp. z o.o. Tel.:+48 22 375 4888 |
France Novartis Pharma S.A.S. Tél: +33 1 55 47 66 00 | Portugal Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600 |
Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 220 | România Novartis Pharma ServicesRomania SRL Tel: +40 21 31299 01 |
Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 | Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 50 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5439 |
Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 | Suomi/Finland Novartis Finland Oy Puh/Tel:+358 (0)10 6133 200 |
Κúπρος Novartis Pharma Services Inc. Τηλ: +357 22 690 690 | Sverige Novartis Sverige AB Tel: +46 8 732 32 00 |
Latvija SIA “Novartis Baltics” Tel: +371 67 887 070 | United Kingdom Novartis Pharmaceuticals UK Ltd. Tel: +44 1276 698370 |
Last update of this leaflet:
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.